Patents by Inventor Darya Burakov
Darya Burakov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12054751Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.Type: GrantFiled: December 15, 2022Date of Patent: August 6, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, James P. Fandl
-
Publication number: 20240018553Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: ApplicationFiled: September 6, 2023Publication date: January 18, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
-
Patent number: 11788102Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: GrantFiled: September 19, 2019Date of Patent: October 17, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
-
Publication number: 20230322956Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.Type: ApplicationFiled: November 10, 2022Publication date: October 12, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL
-
Publication number: 20230304062Abstract: Compositions and methods for the transcription of polynucleotide sequences encoding polypeptides in cells are provided. The cells and methods provided are useful for controlling expression of polypeptides for a wide variety of purposes.Type: ApplicationFiled: October 18, 2022Publication date: September 28, 2023Inventors: Yu Zhao, Michael Goren, Darya Burakov, Gang Chen
-
Publication number: 20230295583Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.Type: ApplicationFiled: December 15, 2022Publication date: September 21, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, James P. Fandl
-
Publication number: 20230287460Abstract: The present inventions provide mammalian cells that comprise multiple Stable Integration Sites. The inventions provide sites introduced genomically into a Genomic Safe Harbor and introduced genomically outside of that particular Genomic Safe Harbor, including but not limited to another Genomic Safe Harbor. Polynucleotides of interest that encode polypeptides or RNAs of interest can be inserted into the Stable Integration Sites provided according to the inventions. The cells and methods of the inventions can be used for the high yield production of any protein, including viral proteins. Additionally, the cells and methods of the inventions are useful for production of viral vectors, such as AAV, antibodies and other proteins.Type: ApplicationFiled: October 18, 2022Publication date: September 14, 2023Inventors: Michael Goren, Darya Burakov, Gang Chen, Yu Zhao, Dipali Deshpande
-
Publication number: 20230193312Abstract: The present inventions provide eukaryotic cells, such as mammalian cells, that comprise adeno-associated virus (AAV) polynucleotides, including AAV capsid proteins (Cap), and are capable of expressing the polypeptides encoded by the AAV polynucleotides, and thereby are capable of producing AAV, including recombinant AAV. The eukaryotic cells also may comprise adenovirus (Ad) polynucleotides. The present inventions also provide methods of expressing AAV polynucleotides, as well as Ad polynucleotides, in eukaryotic cells, such as CHO cells, HEK 293 and BHK cells. The present inventions further provides other products and methods described herein.Type: ApplicationFiled: October 18, 2022Publication date: June 22, 2023Inventors: Michael Goren, Yu Zhao, Alexandros Strikoudis, Darya Burakov, Gang Chen
-
Publication number: 20230130799Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific and bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expression-enhancing locus.Type: ApplicationFiled: September 28, 2022Publication date: April 27, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL, Yu ZHAO
-
Patent number: 11560550Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.Type: GrantFiled: May 4, 2021Date of Patent: January 24, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, James P. Fandl
-
Patent number: 11530277Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.Type: GrantFiled: April 20, 2017Date of Patent: December 20, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Robert Babb, Darya Burakov, Gang Chen, James P. Fandl
-
Patent number: 11512144Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific and bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expression-enhancing locus.Type: GrantFiled: April 20, 2017Date of Patent: November 29, 2022Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Robert Babb, Darya Burakov, Gang Chen, James P. Fandl, Yu Zhao
-
Patent number: 11268109Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: GrantFiled: February 12, 2021Date of Patent: March 8, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
-
Publication number: 20210340564Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: ApplicationFiled: July 2, 2021Publication date: November 4, 2021Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Publication number: 20210254022Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.Type: ApplicationFiled: May 4, 2021Publication date: August 19, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, James P. Fandl
-
Patent number: 11085053Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: GrantFiled: September 10, 2019Date of Patent: August 10, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Publication number: 20210171984Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: ApplicationFiled: February 12, 2021Publication date: June 10, 2021Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
-
Publication number: 20210009714Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: ApplicationFiled: September 18, 2020Publication date: January 14, 2021Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
-
Patent number: 10611831Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: GrantFiled: May 21, 2019Date of Patent: April 7, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande
-
Patent number: RE48651Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: GrantFiled: April 17, 2019Date of Patent: July 20, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande